Valneva SE is a biotechnology company focused on the development, manufacturing, and commercialization of vaccines. The company was founded in 2013 through the merger of Vivalis, a French biopharmaceutical company, and Intercell, an Austrian vaccine developer. Valneva is headquartered in Saint-Herblain, France.
Valneva's core areas of expertise include vaccine research and development, as well as vaccine manufacturing. The company's vaccine portfolio includes vaccines against infectious diseases such as Lyme disease, COVID-19, Japanese encephalitis, and chikungunya. They are also actively involved in the development of vaccine candidates for other diseases.
One of Valneva's significant milestones was the development of its COVID-19 vaccine candidate, VLA2001. The vaccine is based on an inactivated virus and is designed to provide protection against COVID-19. Valneva conducted clinical trials for the vaccine and received regulatory approval for emergency use in several countries.
Valneva collaborates with various organizations, including government agencies and global health institutions, to advance vaccine development and address public health needs. The company's strategic partnerships and alliances play a crucial role in expanding its research capabilities and ensuring a broader reach for its vaccines.
As a biotechnology company, Valneva plays a vital role in public health by developing and providing vaccines that protect people from infectious diseases. The company's ongoing research and development efforts are expected to contribute to the prevention and control of infectious diseases worldwide.